In the breast cancer model, treatment with anti-CTLA-4 given IP and intra-tumor (IT) SS1P injected into one of two tumors growing in the same mouse resulted in complete regressions in 86% of the injected tumors and 53% of non-injected tumors. Here, CTLA4 is linked to breast cancer.